冠状动脉MR血管成像临床应用专家共识(第一版)

2021-09-10 中国医学装备协会磁共振应用专业委员会 中华放射学杂志, 2021,55(09)

冠状动脉MR血管成像(MRCA)作为一种安全有效的无创冠状动脉成像技术已逐步应用于临床,无电离辐射、可不注射对比剂成像的优势使其在冠状动脉疾病诊断中具有独特价值,临床需求逐步增强。MRCA成像技术的相

中文标题:

冠状动脉MR血管成像临床应用专家共识(第一版)

发布日期:

2021-09-10

简要介绍:

冠状动脉MR血管成像(MRCA)作为一种安全有效的无创冠状动脉成像技术已逐步应用于临床,无电离辐射、可不注射对比剂成像的优势使其在冠状动脉疾病诊断中具有独特价值,临床需求逐步增强。MRCA成像技术的相对复杂性是限制其临床推广的主要因素,目前我国业界尚无可遵循的MRCA检查操作规范。本共识针对MRCA检查人员及设备要求、检查适用人群、检查流程、扫描序列选择及参数设置、图像后处理及报告书写等方面提出具体、操作性强的应用标准及建议,以期促进该技术的临床推广及规范化应用。

相关资料下载:
[AttachmentFileName(sort=1, fileName=冠状动脉MR血管成像临床应用专家共识(第一版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=7f75c1c002195161, title=冠状动脉MR血管成像临床应用专家共识(第一版), enTitle=, guiderFrom=中华放射学杂志, 2021,55(09), authorId=0, author=, summary=冠状动脉MR血管成像(MRCA)作为一种安全有效的无创冠状动脉成像技术已逐步应用于临床,无电离辐射、可不注射对比剂成像的优势使其在冠状动脉疾病诊断中具有独特价值,临床需求逐步增强。MRCA成像技术的相, cover=https://img.medsci.cn/2021929/1632844926575_2020535.jpg, journalId=0, articlesId=null, associationId=1989, associationName=中国医学装备协会磁共振应用专业委员会, associationIntro=中国医学装备协会磁共振应用专业委员会, copyright=0, guiderPublishedTime=Fri Sep 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="article_abstract" style="color: #2c3e50;" data-v-da075436=""><span data-v-da075436="">冠状动脉MR血管成像(MRCA)作为一种安全有效的无创冠状动脉成像技术已逐步应用于临床,无电离辐射、可不注射对比剂成像的优势使其在冠状动脉疾病诊断中具有独特价值,临床需求逐步增强。MRCA成像技术的相对复杂性是限制其临床推广的主要因素,目前我国业界尚无可遵循的MRCA检查操作规范。本共识针对MRCA检查人员及设备要求、检查适用人群、检查流程、扫描序列选择及参数设置、图像后处理及报告书写等方面提出具体、操作性强的应用标准及建议,以期促进该技术的临床推广及规范化应用。</span></div>, tagList=[TagDto(tagId=1993, tagName=冠状动脉疾病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1993, guiderKeyword=冠状动脉疾病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=42660, appHits=135, showAppHits=0, pcHits=1597, showPcHits=42525, likes=1, shares=13, comments=11, approvalStatus=1, publishedTime=Wed Sep 29 00:47:26 CST 2021, publishedTimeString=2021-09-10, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=qiushida2, createdTime=Wed Sep 29 00:02:18 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 16:16:45 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=冠状动脉MR血管成像临床应用专家共识(第一版).pdf)])
冠状动脉MR血管成像临床应用专家共识(第一版).pdf
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1201094, encodeId=e1db1201094e6, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7726526611, createdName=ms3000001367310319, createdTime=Wed Mar 09 23:56:40 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074227, encodeId=3f2910e42272b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062422, encodeId=e76610624226e, content=刚学,看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dd85642754, createdName=ms2000001270502233, createdTime=Wed Oct 20 23:58:15 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060311, encodeId=d1ce106031169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/3038963eb9ace715966a110f5dad3e9c.jpg, createdBy=9e0282187, createdName=heromayao, createdTime=Thu Oct 14 07:00:09 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057177, encodeId=9b64105e177c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:08:42 CST 2021, time=2021-10-03, status=1, ipAttribution=)]
    2022-03-09 ms3000001367310319

    很不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1201094, encodeId=e1db1201094e6, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7726526611, createdName=ms3000001367310319, createdTime=Wed Mar 09 23:56:40 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074227, encodeId=3f2910e42272b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062422, encodeId=e76610624226e, content=刚学,看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dd85642754, createdName=ms2000001270502233, createdTime=Wed Oct 20 23:58:15 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060311, encodeId=d1ce106031169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/3038963eb9ace715966a110f5dad3e9c.jpg, createdBy=9e0282187, createdName=heromayao, createdTime=Thu Oct 14 07:00:09 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057177, encodeId=9b64105e177c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:08:42 CST 2021, time=2021-10-03, status=1, ipAttribution=)]
    2021-11-26 H8888888

    不错 学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1201094, encodeId=e1db1201094e6, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7726526611, createdName=ms3000001367310319, createdTime=Wed Mar 09 23:56:40 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074227, encodeId=3f2910e42272b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062422, encodeId=e76610624226e, content=刚学,看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dd85642754, createdName=ms2000001270502233, createdTime=Wed Oct 20 23:58:15 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060311, encodeId=d1ce106031169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/3038963eb9ace715966a110f5dad3e9c.jpg, createdBy=9e0282187, createdName=heromayao, createdTime=Thu Oct 14 07:00:09 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057177, encodeId=9b64105e177c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:08:42 CST 2021, time=2021-10-03, status=1, ipAttribution=)]
    2021-10-20 ms2000001270502233

    刚学,看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1201094, encodeId=e1db1201094e6, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7726526611, createdName=ms3000001367310319, createdTime=Wed Mar 09 23:56:40 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074227, encodeId=3f2910e42272b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062422, encodeId=e76610624226e, content=刚学,看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dd85642754, createdName=ms2000001270502233, createdTime=Wed Oct 20 23:58:15 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060311, encodeId=d1ce106031169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/3038963eb9ace715966a110f5dad3e9c.jpg, createdBy=9e0282187, createdName=heromayao, createdTime=Thu Oct 14 07:00:09 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057177, encodeId=9b64105e177c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:08:42 CST 2021, time=2021-10-03, status=1, ipAttribution=)]
    2021-10-14 heromayao

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1201094, encodeId=e1db1201094e6, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7726526611, createdName=ms3000001367310319, createdTime=Wed Mar 09 23:56:40 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074227, encodeId=3f2910e42272b, content=不错 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:13:40 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062422, encodeId=e76610624226e, content=刚学,看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dd85642754, createdName=ms2000001270502233, createdTime=Wed Oct 20 23:58:15 CST 2021, time=2021-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060311, encodeId=d1ce106031169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/26/3038963eb9ace715966a110f5dad3e9c.jpg, createdBy=9e0282187, createdName=heromayao, createdTime=Thu Oct 14 07:00:09 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057177, encodeId=9b64105e177c9, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:08:42 CST 2021, time=2021-10-03, status=1, ipAttribution=)]
    2021-10-03 H8888888

    学习了

    0

拓展阅读

2016 ESC专家共识:冠状动脉疾病和/或房颤患者出血后抗栓治疗管理

欧洲心脏病学会(ESC,European Society of Cardiology) · 2016-10-27

2017NICE指南:心脏CT是冠状动脉疾病的最佳检验方法

国家卫生和护理研究所(NICE) · 2017-03-27

2017 ACR适宜性标准:慢性胸痛-高度冠状动脉疾病可能性

美国放射学会(ACR,American College of Radiology) · 2017-05-14

血管内超声在冠状动脉疾病中应用的中国专家共识(2018)

中国心血管相关专家小组(统称) · 2018-05-20

冠心病心脏康复基层指南(2020年)

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2021-02-03